Long-Term Follow-up of a Randomized Controlled Trial of Allopurinol Dose Escalation to Achieve Target Serum Urate in People With Gout

REFERENCES

1. 1.↵
   1. Jeyaruban A,
   2. Larkins S,
   3. Soden M

   . Management of gout in general practice--a systematic review. Clin Rheumatol 2015;34:9-16.

   OpenUrlPubMed
2. 2.↵
   1. Scheepers LEJM,
   2. Burde AM,
   3. Arts ICW, et al.

   Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD). Rheumatology 2018;57:1641-50.

   OpenUrl
3. 3.↵
   1. Humphrey C,
   2. Hulme R,
   3. Dalbeth N,
   4. Gow P,
   5. Arroll B,
   6. Lindsay K

   . A qualitative study to explore health professionals’ experience of treating gout: understanding perceived barriers to effective gout management. J Prim Health Care 2016;8:149-56.

   OpenUrl
4. 4.↵
   1. Stamp LK,
   2. Chapman PT,
   3. Barclay ML, et al.

   A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis 2017;76:1522-8.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Stamp L,
   2. Chapman P,
   3. Barclay M, et al.

   Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study. Ann Rheum Dis 2017;76:2065-70.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Khanna D,
   2. Fitzgerald J,
   3. Khanna P, et al.

   2012 American College of Rheumatology guidelines for the management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res 2012;64:1431-46.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Kalichman SC,
   2. Amaral CM,
   3. Swetzes C, et al.

   A simple single-item rating scale to measure medication adherence: further evidence for convergent validity. J Int Assoc Physicians AIDS Care 2009; 8:367-74.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Weinman J,
   2. Graham S,
   3. Canfield M, et al.

   The Intentional Non-Adherence Scale (INAS): initial development and validation. J Psychosom Res 2018;115:110-6.

   OpenUrlPubMed
9. 9.↵
   1. Kim A,
   2. Kim Y,
   3. Kim GT,
   4. Ahn E,
   5. So MW,
   6. Lee SG

   . Comparison of persistence rates between allopurinol and febuxostat as first-line urate-lowering therapy in patients with gout: an 8-year retrospective cohort study. Clin Rheumatol 2020;39:3769-76.

   OpenUrl
10. 10.↵
    1. Proudman C,
    2. Lester SE,
    3. Gonzalez-Chica DA,
    4. Gill TK,
    5. Dalbeth N,
    6. Hill CL

    . Gout, flares, and allopurinol use: a population-based study. Arthritis Res Ther 2019;21:132.

    OpenUrl
11. 11.↵
    1. Stamp LK,
    2. Chapman P,
    3. Hudson B,
    4. Frampton C,
    5. Hamilton G,
    6. Judd A

    . The challenges of managing gout in primary care: results of a best-practice audit. Aust J Gen Pract 2019;48:631-7.

    OpenUrl